INDIAN PHARMACOPOEIA COMMISSION

Ministry of Health & Family Welfare, Govt. of India
Sector-23, Raj Nagar, Ghaziabad 201002

Minutes of 60th Meeting of the Scientific Body of the IPC

Date of Meeting : May 23, 2026
Chairperson : Dr. V. M. Katoch

The list of participants is appended as Enclosure-I.

Welcome and Opening of the Meeting

The 60th meeting of the IPC Scientific Body started with opening remarks by Dr. V. M. Katoch, Chairperson, Scientific Body, IPC. The Scientific Body advised that IPC should present new proposals and future direction plan for the inputs and suggestions of the Scientific Body. Thereafter, the main agenda was presented in the following sequence, and the decisions of the Scientific Body were recorded as below:

Item 1. Introduction and Brief Presentation by the Member Secretary

Dr. V. Kalaiselvan, Member Secretary, presented the progress and key achievements made by the IPC since the last meeting of the Scientific Body.

The Scientific Body noted and appreciated the significant progress made by IPC across various domains, including the expansion of recognition of the Indian Pharmacopoeia to 23 countries, the strengthening of national collaborations through the signing of Memoranda of Understanding (MoUs) with various State Governments and other organizations, and the continued efforts towards training and capacity building of stakeholders through various international meetings, workshops, scientific programmes, and outreach initiatives**.**

Item 2. Confirmation of the Minutes of the 59th Meeting of the SB held on January 19, 2026

Confirmed by the Scientific Body.

Item 3. Action Taken Report on the Minutes of the 59th Meeting of the SB held on January 19, 2026

Noted by the Scientific Body.

MAIN AGENDA

Item 4. Progress of AR&D Division

The Scientific Body reviewed the progress of the AR&D Division with respect to the development of new monographs for inclusion in the IP Addendum 2028. Scientific Body suggested to prioritize the monograph on ‘Semaglutide’. Further, Scientific Body noted updates on the activities related to the international recognition of the IP, IPC’s participation in the Pharmacopoeial Discussion Group (PDG), organizing Expert Working Group (EWG) meetings and Stakeholders' meetings/webinars.

Item 5. Progress of Reference Standard Division (RSD)

The Scientific Body noted the progress made by the Division in the development of new IPRS and impurity standards, updates related to lot changes in reference standards, drug analysis, and revenue generation. Scientific Body suggested that data pertaining to failed samples and lessons learnt may also be presented in future Scientific Body meetings for discussion and review. It was further suggested that IPC should be on-board on the SUGAM portal of the CDSCO.

Item 6. Progress of Microbiology Division

The Scientific Body noted the progress made by Microbiology Division w.r.t. development of new General Chapter, "Application of Water Activity Determination to Non sterile Pharmaceutical Products" and monograph "Water for Hemodialysis" for inclusion in IP. The Scientific Body also noted the progress made in amendments of monographs and General Chapter [such as inclusion of Recombinant Factor C (rFC) and Recombinant Cascade Reagents (rCR) etc. and other amendments]. All these amendments have been uploaded on IPC website for stakeholder comments. The Scientific Body suggested to generate equivalence data while developing alternate methods. Scientific Body also noted the progress made by the Division w.r.t. analytical testing, proficiency Testing programme as per ISO:IEC17043:2023, and research publications.

Item 7. Progress of Biologics Section

The Scientific Body noted the work progress of Biologics Section regarding EWG and stakeholders' meetings, international participation, participation in other meetings and analytical testing. Scientific Body members noted the initiatives taken to create awareness among regulatory officials, blood centres professionals about Blood and Blood Components monographs published in 10th edition of the IP (i.e. IP 2026).

The Scientific Body noted the initiatives taken by IPC for development of IPRS for Biologicals and Biotechnology Derived Therapeutic Products. The Scientific Body also advised that IPC and NIB should have a clear demarcation of molecules to develop IPRS for Biologicals and Biotechnology Derived Therapeutic Products by respective institute and mutual participation in ILC (if facility available) by complimenting each other. This will avoid duplication and ensure efficient use of resources.

Item 8. National/International Mutual Cooperations (MoUs)

Noted by the Scientific Body.

Item 9. Progress of National Formulary of India (NFI)

Scientific Body noted the work progress of the NFI 2026.

Item 10. Progress of Phytopharmaceuticals Division

The Scientific Body observed that the phytopharmaceutical monographs have limited or no apparent industry utilization as of now. In view of this, it was suggested

that the resources available in the Phytopharmaceutical laboratory may be optimally utilized to support activities of other Divisions, wherever feasible.

Item 11. Progress of Quality Assurance (QA) Division

The Scientific Body noted the progress achieved by the Division in maintaining accreditation certifications in accordance with ISO standards. This progress encompasses the execution of proficiency testing (PT) programs, methodical internal quality evaluations, and the provision of extensive training for students.

Item 12. Progress of Pharmacovigilance Programme of India (PvPI)

The progress of the PvPI Division was noted by the Scientific Body. Further, the members of the Scientific Body suggested that the newly developed Monthly Prevented Adverse Drug Reactions Reporting form intended to document adverse drug reactions prevented through pharmacovigilance interventions, should be evaluated in detail before its implementation. In addition, the Scientific Body suggested that PvPI should make a presentation on the impact of PvPI data on public health in the next Scientific Body meeting.

Item 13. Progress of Materiovigilance Programme of India (MvPI)

The Scientific Body noted the progress achieved under the MvPI. With regard to establishing the National Medical Implant Registry, the Scientific Body suggested that detailed consultations may be undertaken with relevant Government organizations and stakeholders, including the CDSCO, ICMR, DHR, and MoHFW to ensure alignment of regulatory considerations and operational feasibility since this activity falls under clinical domain. Under the MvPI, IPC should continue to focus on monitoring adverse events due to medical devices and implants.

Item 14. Progress of Medical Device Division

The Scientific Body noted the progress of the Division and suggested that all signing parties (i.e. IPC, CDSCO, BIS) should be engaged before finalizing the SOP of the development of monographs on medical devices.

Item 15. Progress of Publication Division

Noted by the Scientific Body.

Item 16. Revenue Generation

Noted by the Scientific Body.

Item 17. Any Other Item with the Permission of the Chairperson

None.

The meeting ended with a vote of thanks to the Chairperson and Members of the Scientific Body of IPC by the Member Secretary.

****

Enclosure-I

List of Scientific Body Members Participated

1. Dr. V. M. Katoch, Former DG-ICMR cum Secretary-Department of Health Research and Chairperson, Scientific Body-IPC
2. Dr. Rajeev Singh Raghuvanshi, Drugs Controller General (India) (connected through VC)
3. Prof. Sanjay Singh, Vice Chancellor, Dr Shakuntala Misra University, Lucknow (connected through VC)
4. Dr. D. Srinivasa Reddy, Director, IICT, Hyderabad (connected through VC)
5. Dr. Bikash Medhi, Deptt. of Pharmacology, PGIMER, Chandigarh
6. Dr. A. K. Singh, Former Director General (LS), DRDO, New Delhi (connected through VC)
7. Dr. Ravi P. Singh, Provost. Adani University, Ahmedabad (connected through VC)
8. Dr. Inder Pal Singh, Deptt. of Natural Products, NIPER, Mohali (connected through VC)
9. Dr. Hemant Koshia, Commissioner-Food and Drug Control Administration, Ahmedabad (connected through VC)
10. Sh. D. R. Gahane, Joint Commissioner, Food and Drugs Administration, Mumbai (connected through VC)
11. Dr. C. Hariharan, Director, CDTL, Mumbai
12. Dr. D.J. Kalita, Head-Technical and Regulatory, Zenex Animal Health India Pvt. Ltd., Ahmedabad (connected through VC)
13. Dr. Bhaskar Narayan, Director, CSIR-IITR, Lucknow (connected through VC)
14. Dr. V. Kalaiselvan, Secretary-cum-Scientific Director-IPC and Member Secretary

Special Invitee

1. Prof. Shailendra Saraf, Director, NIPER, Ahmedabad

Leave of Absence

1. Dr. Amulya K. Panda, Former Director, NII, Delhi
2. Dr. Arvind K. Bansal, Professor, Deptt. of Pharmaceutics, NIPER, Mohali
3. Dr. N. Bhaskar, Advisor (Science and Standards), FSSAI, New Delhi
4. Dr. Sunil Gairola, Executive Director, Serum Institute, Pune
5. Prof. Sanjeev Sinha, Deptt. of Medicine, AIIMS, New Delhi
6. Dr. Naresh Bhatnagar, Deptt. of Mechanical Engg., IIT, Delhi
7. Dr. Anil Kumar Tyagi, Chief Scientific Officer, Mankind Pharma Ltd., New Delhi
8. Sh. Zoher Sihorwala, Head-Global Regulatory Affairs, Wockhardt, Aurangabad